Conditions: Anklyosing Spondylitis
Keywords: Ankylosing spondylitis AS Chronic inflammatory disease Inflammatory back pain Secukinumab Prefilled syringe PFS Subcutaneous injection AIN457 AIN457F AIN457F2310 adult
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 219
Healthy volunteers: no

Brief summary:
This study assessed the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who were tolerant to or had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor

Detailed description:

Arms:
arm 1: Secukinumab 75 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks. arm 2: Secukinumab 150 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks arm 3: Placebo subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks

Interventions: intervention 1: Secukinumab (75 mg) intervention 2: Placebo intervention 3: Secukinumab (150 mg)
Intervention descriptions: intervention 1: Secukinumab 75 mg s.c. intervention 2: Placebo intervention 3: Secukinumab 150 mg s.c.

Protocol document: